1. ZEBET, BgVV, Diedersdorfer Weg 1, 12277 Berlin, Germany;
2. Novartis Pharma AG, WSH 2881.228, 4002 Basel, Switzerland;
3. Institut Curie — Section de Recherche, UMR218 CNRS, 26 Rue d'Ulm, 75248 Paris Cedex 05, France;
4. ECVAM, JRC, Institute for Health and Consumer Protection, TP 580, 21020 Ispra (VA), Italy;
5. Bayer AG, FB Toxikologie, Abt. Cancerogenität & Genotoxizität, P.O. Box 10 17 18, 42096 Wuppertal, Germany;
6. Hospital Universitario La Fe, Centro de Investigacion, Avda. de Campanar 21, 46009 Valencia, Spain;
7. Institute for In Vitro Sciences Inc., 21 Firstfield Road, Suite 220, Gaithersburg, MD 20878, USA;
8. L'Oréal, Direction des Sciences du Vivant, Relations Extérieures, 1 Avenue Eugène Schueller, 93600 Aulnay-sous-Bois, France;
9. University of Manchester Dermatology Centre, Photobiology Unit, Hope Hospital, Manchester M6 8HD, UK;
10. Unilever Research, SEAC Toxicology, Colworth House, Sharnbrook, Bedford MK44 1LQ, UK;
11. Universitätsklinikum der Rheinisch-Westfälischen Technischen Hochschule Aachen, Hautklinik, Pauwelsstrasse 30, 52074 Aachen, Germany;
12. The Procter & Gamble Company, Human Safety – Skin Care, Sharon Woods Technical Centre, 11511 Reed Hartman Highway, Cincinnati, OH 45241, USA;
13. Heinrich-Heine-Universität, Hautklinik, Moorenstrasse 5, 40225 Düsseldorf, Germany
14. Beiersdorf AG, Safety Assessment Centre Cosmed, K. St. 4284 – Safety Assessment/Scientific Services, Unnastrasse 48, 20245 Hamburg, Germany;
15. Novartis Pharma AG, PCS-Tox/Path, WSH-2881.3.29, 4002 Basel, Switzerland